To include your compound in the COVID-19 Resource Center, submit it here.

AEM-28: Phase Ib/IIa ongoing

LipimetiX Development LLC began the multiple ascending-dose portion of a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE